Cargando…
Multilevel modeling and value of information in clinical trial decision support
BACKGROUND: Clinical trials are the main method for evaluating safety and efficacy of medical interventions and have produced many advances in improving human health. The Women’s Health Initiative overturned a half-century of harmful practice in hormone therapy, the National Lung Screening Trial ide...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304628/ https://www.ncbi.nlm.nih.gov/pubmed/25540094 http://dx.doi.org/10.1186/s12918-014-0140-0 |
_version_ | 1782354140019556352 |
---|---|
author | Cui, Yuanyuan Murphy, Brendan Gentilcore, Anastasia Sharma, Yugal Minasian, Lori M Kramer, Barnett S Coates, Paul M Gohagan, John K Klenk, Juergen Tidor, Bruce |
author_facet | Cui, Yuanyuan Murphy, Brendan Gentilcore, Anastasia Sharma, Yugal Minasian, Lori M Kramer, Barnett S Coates, Paul M Gohagan, John K Klenk, Juergen Tidor, Bruce |
author_sort | Cui, Yuanyuan |
collection | PubMed |
description | BACKGROUND: Clinical trials are the main method for evaluating safety and efficacy of medical interventions and have produced many advances in improving human health. The Women’s Health Initiative overturned a half-century of harmful practice in hormone therapy, the National Lung Screening Trial identified the first successful lung cancer screening tool and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial overturned decades-long assumptions. While some trials identify unforeseen safety issues or harms, many fail to demonstrate efficacy. Large trials require substantial resources; to ensure reliable outcomes, we must seek ways to improve the predictive information used as the basis of trials. RESULTS: Here we demonstrate a modeling framework for linking knowledge of underlying biological mechanism to evaluate the expectation of trial outcomes. Key features include the ability to propagate uncertainty in biological mechanism to uncertainty in trial outcome and mechanisms for identifying knowledge gaps most responsible for unexpected outcomes. The framework was used to model the effect of selenium supplementation for prostate cancer prevention and parallels the Selenium and Vitamin E Cancer Prevention Trial that showed no efficacy despite suggestive data from secondary endpoints in the Nutritional Prevention of Cancer trial and found increased incidence of high-grade prostate cancer in certain subgroups. CONCLUSION: Using machine learning methods, we identified the parameters of the model that are most predictive of trial outcome and found that the top four are directly related to the rates of reactions producing methylselenol and transporting extracellular selenium into the cell as selenide. This modeling process demonstrates how the approach can be used in advance of a large clinical trial to identify the best targets for conducting further research to reduce the uncertainty in the trial outcome. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12918-014-0140-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4304628 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43046282015-01-24 Multilevel modeling and value of information in clinical trial decision support Cui, Yuanyuan Murphy, Brendan Gentilcore, Anastasia Sharma, Yugal Minasian, Lori M Kramer, Barnett S Coates, Paul M Gohagan, John K Klenk, Juergen Tidor, Bruce BMC Syst Biol Methodology Article BACKGROUND: Clinical trials are the main method for evaluating safety and efficacy of medical interventions and have produced many advances in improving human health. The Women’s Health Initiative overturned a half-century of harmful practice in hormone therapy, the National Lung Screening Trial identified the first successful lung cancer screening tool and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial overturned decades-long assumptions. While some trials identify unforeseen safety issues or harms, many fail to demonstrate efficacy. Large trials require substantial resources; to ensure reliable outcomes, we must seek ways to improve the predictive information used as the basis of trials. RESULTS: Here we demonstrate a modeling framework for linking knowledge of underlying biological mechanism to evaluate the expectation of trial outcomes. Key features include the ability to propagate uncertainty in biological mechanism to uncertainty in trial outcome and mechanisms for identifying knowledge gaps most responsible for unexpected outcomes. The framework was used to model the effect of selenium supplementation for prostate cancer prevention and parallels the Selenium and Vitamin E Cancer Prevention Trial that showed no efficacy despite suggestive data from secondary endpoints in the Nutritional Prevention of Cancer trial and found increased incidence of high-grade prostate cancer in certain subgroups. CONCLUSION: Using machine learning methods, we identified the parameters of the model that are most predictive of trial outcome and found that the top four are directly related to the rates of reactions producing methylselenol and transporting extracellular selenium into the cell as selenide. This modeling process demonstrates how the approach can be used in advance of a large clinical trial to identify the best targets for conducting further research to reduce the uncertainty in the trial outcome. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12918-014-0140-0) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-24 /pmc/articles/PMC4304628/ /pubmed/25540094 http://dx.doi.org/10.1186/s12918-014-0140-0 Text en © Cui et al.; licensee BioMed Central. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Methodology Article Cui, Yuanyuan Murphy, Brendan Gentilcore, Anastasia Sharma, Yugal Minasian, Lori M Kramer, Barnett S Coates, Paul M Gohagan, John K Klenk, Juergen Tidor, Bruce Multilevel modeling and value of information in clinical trial decision support |
title | Multilevel modeling and value of information in clinical trial decision support |
title_full | Multilevel modeling and value of information in clinical trial decision support |
title_fullStr | Multilevel modeling and value of information in clinical trial decision support |
title_full_unstemmed | Multilevel modeling and value of information in clinical trial decision support |
title_short | Multilevel modeling and value of information in clinical trial decision support |
title_sort | multilevel modeling and value of information in clinical trial decision support |
topic | Methodology Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304628/ https://www.ncbi.nlm.nih.gov/pubmed/25540094 http://dx.doi.org/10.1186/s12918-014-0140-0 |
work_keys_str_mv | AT cuiyuanyuan multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport AT murphybrendan multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport AT gentilcoreanastasia multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport AT sharmayugal multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport AT minasianlorim multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport AT kramerbarnetts multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport AT coatespaulm multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport AT gohaganjohnk multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport AT klenkjuergen multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport AT tidorbruce multilevelmodelingandvalueofinformationinclinicaltrialdecisionsupport |